Article
Oncology
Chella Krishna Vadivel, Maria Gluud, Sara Torres-Rusillo, Lasse Boding, Andreas Willerslev-Olsen, Terkild B. Buus, Tea Kirkegaard Nielsen, Jenny L. Persson, Charlotte M. Bonefeld, Carsten Geisler, Thorbjorn Krejsgaard, Anja T. Fuglsang, Niels Odum, Anders Woetmann
Summary: This study demonstrates the nuclear localization of JAK3 in malignant T cells and its interactions with key nuclear proteins, suggesting a novel non-canonical role in cutaneous T cell lymphoma.
Article
Dermatology
D. M. Weiner, Joseph S. Durgin, Maria Wysocka, Alain H. Rook
Summary: In recent decades, immunotherapy has emerged as an effective treatment option for patients with CTCL by stimulating the immune system to clear malignant T cells and repair immune dysfunction. Understanding the interactions with the immune system and treatment outcomes are crucial in utilizing established and emerging immunotherapeutic options for CTCL treatment.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Dermatology
Joseph S. Durgin, David M. Weiner, Maria Wysocka, Alain H. Rook
Summary: CTCLs are malignancies of skin-trafficking T cells, with patients experiencing immune dysfunction and susceptibility to infections. Therapies stimulating immunity show superior outcomes compared to conventional chemotherapy. Recent research has identified potential therapeutic targets by better understanding the pathogenesis of immune deficits in CTCL patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Hematology
Sara Beygi, George E. Duran, Sebastian Fernandez-Pol, Alain H. Rook, Youn H. Kim, Michael S. Khodadoust
Summary: Resistance to mogamulizumab in mycosis fungoides and Sezary syndrome is often associated with loss of CCR4 expression and emergence of CCR4 genomic alterations. This finding has significant implications for the management and monitoring of patients receiving mogamulizumab and the development of future CCR4-directed therapies.
Article
Multidisciplinary Sciences
Xiangjun Liu, Shanzhao Jin, Simeng Hu, Ruoyan Li, Haihao Pan, Yi Liu, Pan Lai, Deshu Xu, Jingru Sun, Ziyang Liu, Yumei Gao, Yifan Zhao, Fengjie Liu, Yu Xiao, Yingyi Li, Yujie Wen, Zhuojing Chen, Bufang Xu, Yuchieh Lin, Menglong Ran, Qianxi Li, Shuxia Yang, Hang Li, Ping Tu, Muzlifah Haniffa, Sarah A. Teichmann, Fan Bai, Yang Wang
Summary: Cutaneous T cell lymphoma (CTCL) is a heterogeneous group of non-Hodgkin lymphoma characterized by clonal malignant T cells. This study analyzed CTCL patient samples using single-cell RNA-seq, TCR and whole-exome sequencing, revealing the molecular profiles of malignant T cells and their association with the microenvironment and clinical outcomes.
NATURE COMMUNICATIONS
(2022)
Review
Dermatology
Leah L. Thompson, Steven T. Chen, Andrew Lawton, Alexandra Charrow
Summary: Palliative care has been proven to benefit patients with life-limiting diseases, but its usage among those with severe dermatologic conditions is limited, despite significant unmet care needs. This review examines current palliative care patterns in dermatology, highlighting areas for improvement and future research.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Chrysostomos Avgeros, Aikaterini Patsatsi, Dimitrios Dimitriadis, Andigoni Malousi, Triantafyllia Koletsa, Despoina Papathemeli, Antonia Syrnioti, Paraskevi Avgerou, Elizabeth Lazaridou, Georgios Tzimagiorgis, Elisavet Georgiou
Summary: This study evaluates the plasma levels of miR-146a and miR-155 in Mycosis Fungoides (MF) patients and investigates their association with SNPs of their genes. The results show that the plasma levels of miR-146a and miR-155 are significantly higher in MF patients compared to controls, especially in early and advanced stages. miR-155 levels are significantly higher in patients with skin tumors or erythroderma. The presence of specific SNPs is associated with the expression of miRs and potentially with disease susceptibility.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cell Biology
Amy Xiao, Oleg E. Akilov
Summary: The loss of CD47 on aging cells signals macrophages to eliminate the target. CD47 acts as a "do-not-eat-me" sign that prevents macrophagal phagocytosis by interacting with its ligand SIRP alpha. Malignant lymphocytes highly express CD47, making them ideal candidates for targeted anti-CD47 therapies. There are various types of anti-CD47-SIRP alpha therapeutic molecules, including monoclonal antibodies, bioengineered proteins, miRNAs, and bispecific antibodies. Blocking the CD47-SIRP alpha axis in combination with targeting secondary tumor microenvironment (TME) may enhance the effectiveness of current immunotherapeutic approaches.
Review
Biochemistry & Molecular Biology
Shuichi Nakai, Eiji Kiyohara, Rei Watanabe
Summary: CTCL is a heterogeneous group of non-Hodgkin lymphoma, mainly including MF and SS, with malignant cells possibly originating from different T cell phenotypes. The pathogenesis and therapeutic strategies for CTCL remain unclear due to the similar characteristics between malignant cells and anti-tumor T cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Dermatology
Zhen Han, Renee J. Estephan, Xiwei Wu, Chingyu Su, Yate-Ching Yuan, Hanjun Qin, Sung Hee Kil, Corey Morales, Daniel Schmolze, James F. Sanchez, Lei Tian, Jianhua Yu, Marcin Kortylewski, Steven T. Rosen, Christiane Querfeld
Summary: Cutaneous T cell lymphoma (CTCL) is a malignant tumor characterized by chronic inflammation. This study found that miR-155-5p, miR-130b-3p, and miR-21-3p positively correlated with immune checkpoint gene expression in CTCL and were enriched in the IL-6/Jak/signal transducer and activator of transcription signaling pathway.
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2022)
Article
Dermatology
Amrita Goyal, Daniel O'Leary, Kavita Goyal, Krishnan Patel, David Pearson, Murali Janakiram
Summary: Patients with cutaneous T-cell lymphoma (CTCL) have an increased risk of developing second malignancies, especially Hodgkin and non-Hodgkin lymphoma, lung cancer, bladder cancer, and melanoma. These findings provide evidence of a population at increased risk of malignancy, emphasizing the importance of early detection for decreasing the morbidity burden of second malignancies.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Oncology
Tony T. Jiang, Oleg Kruglov, Gloria H. Y. Lin, Angela Minic, Kimberly Jordan, Robert A. Uger, Mark Wong, Yaping Shou, Oleg E. Akilov
Summary: Identification of cancer progression events is crucial for therapy development. Mycosis fungoides serves as a valuable model, revealing expansion of exhausted immune cells around malignant cells, hindering immune system clearance. Novel anti-CD47 immunotherapy reduces exhausted T cells and expands NK and CD8(+) T cells, with interferon-alpha enhancing therapeutic benefits. CD47 proves a promising therapeutic target for mycosis fungoides.
Article
Biochemistry & Molecular Biology
Minami Sakamoto, Tomomitsu Miyagaki, Hiroaki Kamijo, Tomonori Oka, Hikari Boki, Naomi Takahashi-Shishido, Hiraku Suga, Makoto Sugaya, Shinichi Sato
Summary: CD147 and CypA are overexpressed in tumor cells of mycosis fungoides and Sezary syndrome patients, and CypA is also expressed by epidermal keratinocytes in lesional skin. Serum CypA levels are elevated and correlated with disease severity markers. Anti-CD147 and/or anti-CypA antibodies can suppress the proliferation of CTCL cell lines by downregulating signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Cell Biology
Melika Motamedi, Maggie Z. X. Xiao, Aishwarya Iyer, Robert Gniadecki
Summary: Mycosis fungoides (MF) has varying prognoses at different stages, with late stages associated with an increased risk of mortality. This study identified transcriptomic changes involved in MF pathogenesis and progression, highlighting 15 genes that play a role in MF progression.
Article
Medicine, General & Internal
Christiane Querfeld, Theresa Pacheco, Bradley Haverkos, Gary Binder, James Angello, Brian Poligone
Summary: The study found an association between clinician case volume and treatment duration as well as early discontinuation of chlormethine gel, with clinicians seeing more patients performing better in terms of treatment outcomes. However, a case volume as low as five patients appeared to be a threshold for avoiding early treatment discontinuation.
FRONTIERS IN MEDICINE
(2021)